Meridian Bioscience

Meridian Bioscience Retained Earnings

The Retained Earnings of Meridian Bioscience (VIVO) as of Oct 27, 2026 is 223.16 M USD. In the previous year, Retained Earnings was 180.70 M USD — a change of 23.50% (higher).

Retained Earnings

223.16 MUSD

YoY

23.50%

Last updated:

Retained Earnings of Meridian Bioscience is 2022 223.16 M USD. Retained Earnings of Meridian Bioscience was 2021 180.70 M USD. It decreases by 23.50% higher compared to the previous year.

The Meridian Bioscience Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2015
51.10 M USD
Jan 1, 2016
49.60 M USD
Jan 1, 2017
46.90 M USD
Jan 1, 2018
49.60 M USD
Jan 1, 2019
63.10 M USD
Jan 1, 2020
109.30 M USD
Jan 1, 2021
180.70 M USD
Jan 1, 2022
223.16 M USD
The Meridian Bioscience Retained Earnings history
YEARRetained EarningsYoY
223.16 MUSD+23.50%
180.70 MUSD+65.33%
109.30 MUSD+73.22%
63.10 MUSD+27.22%
49.60 MUSD+5.76%
46.90 MUSD-5.44%
49.60 MUSD-2.94%
51.10 MUSD+4.50%
48.90 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Retained Earnings of Meridian Bioscience is 223.16 M USD in 2022.

Retained Earnings of Meridian Bioscience changed from 180.70 M USD to 223.16 M USD, representing a 23.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Meridian Bioscience

All Key Metrics — Meridian Bioscience